RxDoctor Payments Data

Minar Chhetry, MD

Cardiovascular Disease · Murfreesboro, TNNPI 1528412046

Payments from drug & device makers

$2,569in general payments, 2019–2025

Across 66 payments — averaging $38.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Heartflow, Inc.$889
  • Amgen$393
  • Boston Scientific$378
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$293
  • Abbott$148
  • Pfizer$132
  • plus $338 from 10 others

What the payments were for

  • Food & beverage$2,45195%
  • Education$1185%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,569 in reported general payments places this provider in the 50th percentile of 429 cardiovascular disease providers in Tennessee.

See all cardiovascular disease providers in Tennessee

Medicare billing

Part B allowed, 2024
$132,929
Medicare patients
868
Services billed
1,972

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban250$249,975
JardianceEmpagliflozin48$61,291
XareltoRivaroxaban40$51,070
EntrestoSacubitril/Valsartan33$47,085
Ezetimibe62$3,061
Metoprolol Succinate171$2,825
Atorvastatin Calcium168$2,217
Midodrine Hcl11$1,249
Losartan Potassium93$1,183
Ranolazine ErRanolazine14$1,126
Potassium Chloride61$961
Diltiazem 24hr Er (Cd)Diltiazem Hcl24$825
Chlorthalidone32$741
Bumetanide19$708
Furosemide128$701

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$132$249,975250 claims
Boehringer IngelheimJardiance$24$61,29148 claims
Johnson & JohnsonXarelto$55$51,07040 claims
NovartisEntresto$62$47,08533 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 429 cardiovascular disease providers in Tennessee.

Other cardiovascular disease in Murfreesboro

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →